Shares of Insmed tumbled as low as 36.8%, or $1.60, on 10 October after the Monmouth Junction, New Jersey-based firm revealed the US FDA plans to continue the clinical hold placed on the company's Phase III trials for Arikace (liposomal amikacin for inhalation) in cystic fibrosis patients with Pseudomonas lung infections.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Green Cross Corp has acquired rights in South Korea to aRigen Pharmaceuticals' lotilibcin (WAP-8294A2), in what is the first licensing deal for the novel anti-MRSA agent.

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions